Australia’s opportunity to turn biotech into global growth
How Australian biotech can use funding, clinical research and global markets to drive growth.
Beyond the numbers: Explore the trends and ideas shaping Australian business. Listen now.
16 Jul 2026 5 min read

The message is a reassuring one for exporters: EMDG remains a highly valued program that helps Australian small and medium businesses grow, innovate and diversify into international markets, and the review proposes a set of practical improvements aimed at making it work better for applicants and better align with government trade priorities.
For current and prospective EMDG applicants, the review offers encouraging signs that stakeholder feedback has been heard, and that future rounds may be simpler, fairer and more predictable to navigate.
The review confirms what many exporters have told us for years. EMDG plays an important role in supporting Australian SMEs to enter and expand into overseas markets, giving businesses the confidence to undertaken marketing and promotional activities they might not otherwise pursue, while also encouraging stronger planning, ambition and innovation.
Rather than a whole overhaul, the report appears to have taken a measured approach, focusing on targeted changes that address the most significant pain points from Round 4, without adding unnecessary burden on business.
The review makes 29 recommendations in total. The ones most likely to shape the applicant experience are:
The full report and recommendations are available here.
Importantly, the review recognises the value of the EMDG program and proposes refinements designed to improve applicant experience while preserving the core benefits of the program. It also encourages stronger connections between EMDG and complementary government support including advisory services, export finance through Export Finance Australia, in-market support and business innovation programs. For exporters, this means the potential for a more joined-up, whole-of-government approach that goes beyond a single grant.
The Australian Government is now considering the recommendations and will decide which changes are implemented for future rounds. In the meantime, the existing EMDG framework remains in place.
For businesses currently exporting, or considering international expansion, the review provides a positive signal that the EMDG program will continue to be a cornerstone of Australia's export support landscape, with a sharper focus on accessibility, transparency and outcomes for applicants.
It is also worth remembering that following the last independent review in 2020, significant reforms were implemented so there is good reason to be optimistic that this review may drive further meaningful improvements. Importantly, the report notes that its recommendations have been designed to avoid placing unnecessary additional burden on stakeholders, which points to a smoother transition for applicants going forward.
Our EMDG specialists support businesses at every stage of the application and grant management process, from eligibility assessments and application preparation through to milestone reporting and compliance.
If you would like to discuss how the proposed changes may affect your business or explore whether EMDG could support your international growth plans, please get in touch with our team.
Article contributed to by Alana Bayliss - Senior Manager - R&D Tax (Innovation Incentives)
How Australian biotech can use funding, clinical research and global markets to drive growth.
R&D Tax Incentive reforms, RDTI reforms, R&D tax offset, innovation incentives, refundable R&D offset, non-refundable R&D offset, supporting R&D activities, Treasury consultation, research and development tax incentive, Federal Budget 2026-27, R&D tax changes, Australia R&D incentives, Innovation Incentives, R&D claims
In this edition of our Australian International Tax Update, we summarise recent significant Australian tax developments, examine their practical impact, and outline actions that multinational groups, foreign investors, private equity funds and international advisers should consider.